Toggle menu

RAMPP trial

Start date:
2017
End date:
September 2017
Co-ordinated by:
Bernadette Gallagher
Main trial site:
RIE

The RAMPP study aims to investigate the use of a pleural vent (rocket) versus standard care in patients with Primary Spontaneous Pnuemothorax in a randomised controlled trial.

Eligibility Criteria

Inclusion criteria:
1. Presenting with primary spontaneous pneumothorax as confirmed by a chest radiograph or a CT scan.
2. Age >= 18 years old and <= 55 years old.
3. Ability to consent to participation.

Exclusion Criteria
1. Known or suspected underlying lung disease (including >20 pack year smoking history).
2. Evidence of tension pneumothorax (these patients should be treated immediately as medical emergencies).
3. Females who are pregnant or lactating.
4. Inability to consent or comply with the trial requirements.
5. Contraindication to thoracic procedure. (Only applies to patients being enrolled into Intervention or Control arms – i.e. not observational cohort).
6. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.

 

Funding:  Medical Research Council and the National Institute for Health Research (UK).

Sponsor:  University of Oxford, Churchill Hospital (UK)

Setting: This is a multi-centre study being co-ordinated from Oxford.

 

 

Local PI

Dr Marie-Clare Harris

Consultant in Emergency Medicine

Research Team

Bernadette Gallagher

Senior Research Nurse

Allan MacRaild

Senior Research Nurse

More EMERGE Trials

This trial is a two arm, multicentre parallel group, randomised controlled, open label trial comparing intravenous levetiracetam to intravenous phenytoin for the treatment of convulsive status epilepticus (CSE) in children, young people and young adults.

Read more

EcLiPSE

Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial

Intervention
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.

Read more

RAMPP trial

RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax

Evaluating the kinetics of cardiac biomarkers after ST-segment Elevation myocardial infarction

Read more

HighSTEACS Bioresource